Sangamo Therapeutics Inc. is a genomic medicine company focused on neurology. It is developing epigenetic gene-regulation therapies for neurological disorders, along with novel adeno-associated virus (AAV) capsids to improve gene-delivery performance.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Sangamo is focused on developing epigenetic regulation therapies using its zinc finger (ZF) technology platform for serious neurological diseases. The company is a leader in the research and development of zinc finger proteins (ZFPs), which regulate the genome through interactions with DNA and regulatory proteins. The current focus is on advancing core preclinical neurology programs from research to preclinical and clinical development. The company has collaborations with biopharmaceutical companies to leverage therapeutic and clinical expertise and commercial resources, aiming to bring medicines more rapidly to patients. The R&D unit of Sangamo is primarily responsible for advancing product candidates from research programs to preclinical and clinical development. The unit is engaged in developing the company's core preclinical neurology programs and managing collaborations with biopharmaceutical companies to support research and development efforts. Some of its pipeline drugs include ST-503 in phase 2 to treat idiopathic small fiber neuropathy; ST-920 in a phase 1/2 study to treat Fabry Disease; SB-525/giroctocogene fitelparvovec in a phase 1/2 study to treat Hemophilia A; giroctocogene fitelparvovec in a phase 3 study to treat Hemophilia A; TX200 in a phase 1/2 study to treat Renal Transplantation; and BIVV003 in phase 1/2 study to treat Sickle Cell Disease. In FY2025, the company spent US$112.6 million on its R&D activities, which grew 1% YoY.